2 not yet recruiting, 1 active not recruiting. 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Qiming Wang: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC Combined group of ensatinib and arotinib - ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib | Phase 4 | Not yet recruiting | Qiming Wang | 80 | 2026-07-01 | 2026-06-26 |
| High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis Combination therapy prospective cohort - Non Small Cell Lung Cancer, EGFR Mutation | Phase 2 | Not yet recruiting | Qiming Wang | 100 | 2025-05-15 | 2025-05-14 |
| A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases Lung Cancer (NSCLC), Leptomeningeal Cancer | Active not recruiting | Qiming Wang | 500 | 2025-03-01 | 2025-04-15 |
Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (1) · Meningeal Carcinomatosis (1) · Neoplasm Metastasis (1)
China (1)